Log in to your Inderes Free account to see all free content on this page.
Implantica
42.4 SEK +0.95%1 investor is following this company
Implantica is active in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes implantable medical instruments, which are further used for the treatment of diseases that affect the esophagus. In addition to the main business, service and related ancillary services are also offered, especially focused on eHealth. Implantica operates worldwide, with the largest presence in North America and Europe.
Revenue
15.7M
EBIT %
-1,548.94 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
IMP A SDB
Daily low / high price
42 / 44.15
SEK
Market cap
50.16B SEK
Turnover
1.53M SEK
Volume
36K
Latest videos
Financial calendar
Interim report
15.11.2024
Annual report
14.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Peter Forsell | 47.4 % | 47.4 % |
Handelsbanken Fonder | 8.6 % | 8.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Implantica welcomes 23 top anti-reflux surgeons from 17 leading centers in the first User meeting in Spain, 1.5 years post country launch
Implantica shares a landmark review article on standard of care Nissen Fundoplication anti-reflux surgery - in light of the recently announced excellent RefluxStop[TM] 5-year results
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio